The AstraZeneca Centre for Genomics Research has tapped DNAnexus to develop a secure genomics informatics environment for analyzing 2 million genomes.
DNAnexus customers now have a choice of two cloud platforms and ancillary tools and the company has access to a wider pool of potential users.
Researchers participating in ORIEN's Avatar program can use the platform to manage, share, integrate, and analyze molecular data from consenting patients.
The current arrangement builds on an existing agreement signed last year that allowed Garvan to use DNAnexus' platform for its genomics activities.
The WGS service will be provided by Genome.One, a new health information company owned by and based at the Garvan Institute of Medical Research in Sydney.
The combined solution gives customers access to the bioinformatics tools and genomic intelligence to help them analyze data and make business decisions.
The tools the partners plan to develop will help researchers optimize genomic analysis workflows and better identify links between genes and disease.
In a JNCCN paper, the investigators discussed their efforts to comprehensively characterize a single patient's breast tumor and test potential treatments.
Under the terms of the agreement, DNAnexus will make Sapio's LIMS software available on its genomics infrastructure.
The FDA established the platform to allow scientists to test their NGS assays and to advance the regulatory science for assessing genomic tests and software.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.